Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’

The pharmaceutical industry and the UK government are beginning a series of discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.

Europe United Kingdom

More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences

In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.

Europe United Kingdom

UK Statutory Scheme Rebate Rise Could Cause Product Shortages & Launch Delays

The pharmaceutical industry is calling on the government to take steps to restore the UK as a location for life sciences investment and recognize the role of competition in the branded generics market, but it will need strong evidence to make the most convincing case.

Europe United Kingdom

UK Pharma Industry Facing Difficult Price Scheme Talks in 2023

Negotiations on the successor to the UK’s 2019 voluntary drug pricing scheme are due to start in April 2023. The industry body, the ABPI, is calling for a clean sheet approach, but others suggest that could make it almost impossible to reach agreement in less than a year and that reform may be a more realistic proposition.

Europe United Kingdom

Companies Planning UK Investment Cuts Over Repayments Predicted for 2023

Many pharma firms are considering cutting their investment in clinical trials or reducing their supply to the UK market next year, a survey by industry group EMIG found.

Europe United Kingdom

UK HTA Body To Conduct More Appraisals, And Faster, Through Proportionate Approach

Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.

Europe United Kingdom
See All
UsernamePublicRestriction

Register